1. Home
  2. SU vs REGN Comparison

SU vs REGN Comparison

Compare SU & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Suncor Energy  Inc.

SU

Suncor Energy Inc.

HOLD

Current Price

$66.48

Market Cap

67.5B

Sector

Energy

ML Signal

HOLD

Logo Regeneron Pharmaceuticals Inc.

REGN

Regeneron Pharmaceuticals Inc.

HOLD

Current Price

$739.71

Market Cap

77.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SU
REGN
Founded
1917
1988
Country
Canada
United States
Employees
N/A
N/A
Industry
Integrated oil Companies
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
67.5B
77.5B
IPO Year
1998
1995

Fundamental Metrics

Financial Performance
Metric
SU
REGN
Price
$66.48
$739.71
Analyst Decision
Strong Buy
Buy
Analyst Count
2
24
Target Price
$68.50
$819.54
AVG Volume (30 Days)
5.4M
483.3K
Earning Date
05-05-2026
04-29-2026
Dividend Yield
2.61%
0.50%
EPS Growth
N/A
8.19
EPS
N/A
41.48
Revenue
N/A
$5,872,227,000.00
Revenue This Year
N/A
$11.88
Revenue Next Year
$1.59
$10.31
P/E Ratio
$15.79
$18.25
Revenue Growth
N/A
20.82
52 Week Low
$30.79
$476.49
52 Week High
$65.65
$821.11

Technical Indicators

Market Signals
Indicator
SU
REGN
Relative Strength Index (RSI) 84.51 43.05
Support Level $38.37 $725.92
Resistance Level N/A $788.69
Average True Range (ATR) 1.69 16.88
MACD 0.39 -1.00
Stochastic Oscillator 98.81 19.40

Price Performance

Historical Comparison
SU
REGN

About SU Suncor Energy Inc.

Suncor Energy Inc is an integrated energy company. The company's operations span the full energy value chain, including oil sands mining and in situ operations, upgrading, offshore production, petroleum refining in Canada and the U.S., marketing and trading, and nationwide PetroCanada retail and wholesale networks delivering reliable energy that fuels economic growth and meets the needs of customers across Canada and globally. It also conducts energy trading activities focused principally on the marketing and trading of crude oil, natural gas, byproducts, refined products, & power. The company's operating segments include Oil Sands, Exploration & Production, Refining & Marketing (R&M), & Corporate & eliminations. Geographically, the company generates a majority of its revenue from Canada.

About REGN Regeneron Pharmaceuticals Inc.

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

Share on Social Networks: